Chronic Liver Disease Management

Introduction to Chronic Liver Disease

The American Association for the Study of Liver Diseases recommends that the treatment of chronic liver disease should target the specific underlying cause, with antiviral therapy recommended for viral hepatitis, complete abstinence for alcoholic liver disease, and lifestyle modifications for non-alcoholic fatty liver disease 1

The European Association for the Study of the Liver states that chronic liver disease has several major etiologies that require specific targeted therapies, including viral hepatitis (B and C) 2
The American Association for the Study of Liver Diseases recommends that for chronic hepatitis B, first-line treatments include entecavir, tenofovir, or peginterferon alfa-2a 1
The American Association for the Study of Liver Diseases recommends that treatment is recommended for patients with elevated ALT and HBV DNA ≥2000 IU/mL 1
The Journal of Hepatology reports that direct-acting antivirals (DAAs) have revolutionized treatment for chronic hepatitis C with high cure rates 2
The American Association for the Study of Liver Diseases recommends that all patients with cirrhosis and detectable HBV DNA should receive treatment regardless of ALT levels 1

The American Association for the Study of Liver Diseases recommends that weight loss of 7-10% through caloric restriction and regular physical activity improves liver histology, reduces inflammation, and can improve fibrosis 3
The American Association for the Study of Liver Diseases recommends that a Mediterranean diet pattern reduces liver fat even without weight loss 3
The American Association for the Study of Liver Diseases recommends that at least 150-300 minutes of moderate-intensity aerobic exercise per week is beneficial for patients with NAFLD/NASH 3

The European Association for the Study of the Liver recommends that for chronic liver disease without cirrhosis, treatment of the underlying cause can prevent progression to cirrhosis 2
The American Association for the Study of Liver Diseases recommends that for HBV-related cirrhosis, first-line options include entecavir, tenofovir, or peginterferon alfa-2a with lifelong therapy typically required 1
The American Gastroenterological Association recommends that patients with cirrhosis should be screened for gastroesophageal varices according to practice guidelines 4

The European Association for the Study of the Liver recommends that vaccination against hepatitis B reduces the risk of HCC and is recommended for all newborns and high-risk groups 2
The American Association for the Study of Liver Diseases recommends that early treatment of underlying liver diseases before progression to cirrhosis is the most effective approach for preventing HCC and liver-related mortality 1

The Journal of Hepatology reports that patients with HCV-associated cirrhosis and HCC treated with curative intent maintain a high rate of HCC recurrence even after subsequent DAA therapy resulting in sustained viral response 2
The American Gastroenterological Association recommends that when steatosis and steatohepatitis are evident in patients with other types of chronic liver disease, it is important to assess for metabolic risk factors and alternate etiologies 4
The American Association for the Study of Liver Diseases recommends that HIV-HBV coinfection is associated with higher HBV DNA levels, more rapid progression to cirrhosis, and 14-fold higher liver-related mortality 1

The American Association for the Study of Liver Diseases recommends that HBV DNA and ALT levels should be monitored every 3-6 months during therapy 1
The American Association for the Study of Liver Diseases recommends that patients on nucleos(t)ide analogues should be monitored for virologic breakthrough and renal function 1
The American Association for the Study of Liver Diseases recommends that lifelong HCC surveillance is required for cirrhotic patients, even after viral clearance 1

Patients with cirrhosis should be referred for transplantation when they develop evidence of hepatic dysfunction or when they experience their first major complication, according to the American Association for the Study of Liver Diseases 5
Every therapeutic option should be carefully considered before committing a patient to liver transplantation due to the need for long-term immunosuppressive therapy, as recommended by the American Association for the Study of Liver Diseases 5
Patients with type I hepatorenal syndrome should have an expedited referral for liver transplantation, as suggested by the American Association for the Study of Liver Diseases 5

Vitamin D deficiency is common and correlates with disease severity; supplementation is recommended for levels below 20 ng/ml to achieve levels above 30 ng/ml, according to the European Association for the Study of the Liver 6
Vitamin K supplementation should be considered in patients with jaundice or cholestatic liver disease, as recommended by the European Association for the Study of the Liver 6
Water-soluble vitamin deficiencies may develop rapidly due to diminished hepatic storage; multivitamin supplementation is reasonable in decompensated patients, according to the European Association for the Study of the Liver 6
Sodium intake should not be reduced below 60 mmol/d in patients with ascites, as suggested by the European Association for the Study of the Liver 6

Bone densitometry should be evaluated in patients with previous fragility fractures, those treated with corticosteroids, and before liver transplantation, according to the European Association for the Study of the Liver 7
Calcium and vitamin D supplementation is recommended for patients with chronic liver disease, as suggested by the European Association for the Study of the Liver 7
Bisphosphonates may be considered for patients with established osteoporosis, particularly those with primary biliary cholangitis, according to the European Association for the Study of the Liver 7